KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis

FRA:PHI1 • NL0000009538

26.58 EUR
-0.99 (-3.59%)
Last: Feb 11, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

Taking everything into account, PHI1 scores 3 out of 10 in our fundamental rating. PHI1 was compared to 63 industry peers in the Health Care Equipment & Supplies industry. PHI1 has a bad profitability rating. Also its financial health evaluation is rather negative. PHI1 has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • PHI1 had positive earnings in the past year.
  • PHI1 had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
  • Of the past 5 years PHI1 4 years had a positive operating cash flow.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

1.2 Ratios

  • The Return On Assets of PHI1 (0.63%) is worse than 61.90% of its industry peers.
  • With a Return On Equity value of 1.56%, PHI1 is not doing good in the industry: 61.90% of the companies in the same industry are doing better.
  • Looking at the Return On Invested Capital, with a value of 3.95%, PHI1 is doing worse than 61.90% of the companies in the same industry.
Industry RankSector Rank
ROA 0.63%
ROE 1.56%
ROIC 3.95%
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • PHI1's Profit Margin of 0.93% is on the low side compared to the rest of the industry. PHI1 is outperformed by 61.90% of its industry peers.
  • PHI1 has a Operating Margin of 6.10%. This is comparable to the rest of the industry: PHI1 outperforms 41.27% of its industry peers.
  • In the last couple of years the Operating Margin of PHI1 has declined.
  • With a Gross Margin value of 43.49%, PHI1 is not doing good in the industry: 76.19% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of PHI1 has remained more or less at the same level.
Industry RankSector Rank
OM 6.1%
PM (TTM) 0.93%
GM 43.49%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHI1 is destroying value.
  • The number of shares outstanding for PHI1 has been reduced compared to 1 year ago.
  • Compared to 5 years ago, PHI1 has more shares outstanding
  • PHI1 has a worse debt/assets ratio than last year.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • An Altman-Z score of 2.06 indicates that PHI1 is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • PHI1 has a Altman-Z score (2.06) which is in line with its industry peers.
  • The Debt to FCF ratio of PHI1 is 14.51, which is on the high side as it means it would take PHI1, 14.51 years of fcf income to pay off all of its debts.
  • PHI1 has a Debt to FCF ratio of 14.51. This is in the lower half of the industry: PHI1 underperforms 60.32% of its industry peers.
  • PHI1 has a Debt/Equity ratio of 0.69. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.69, PHI1 is doing worse than 73.02% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 14.51
Altman-Z 2.06
ROIC/WACC0.61
WACC6.49%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

2.3 Liquidity

  • PHI1 has a Current Ratio of 1.32. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
  • PHI1's Current ratio of 1.32 is on the low side compared to the rest of the industry. PHI1 is outperformed by 61.90% of its industry peers.
  • PHI1 has a Quick Ratio of 1.32. This is a bad value and indicates that PHI1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.86, PHI1 is doing worse than 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.86
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • PHI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.15%, which is quite good.
  • The Earnings Per Share has been decreasing by -7.17% on average over the past years.
  • Looking at the last year, PHI1 shows a decrease in Revenue. The Revenue has decreased by -1.43% in the last year.
  • PHI1 shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.00% yearly.
EPS 1Y (TTM)15.15%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%12.5%
Revenue 1Y (TTM)-1.43%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-1.71%

3.2 Future

  • PHI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.28% yearly.
  • The Revenue is expected to grow by 3.00% on average over the next years.
EPS Next Y4.94%
EPS Next 2Y4.81%
EPS Next 3Y7.44%
EPS Next 5Y10.28%
Revenue Next Year-2.27%
Revenue Next 2Y0.25%
Revenue Next 3Y1.58%
Revenue Next 5Y3%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • PHI1 is valuated rather expensively with a Price/Earnings ratio of 17.96.
  • PHI1's Price/Earnings ratio is rather cheap when compared to the industry. PHI1 is cheaper than 85.71% of the companies in the same industry.
  • PHI1 is valuated rather cheaply when we compare the Price/Earnings ratio to 28.18, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 17.47 indicates a rather expensive valuation of PHI1.
  • Based on the Price/Forward Earnings ratio, PHI1 is valued a bit cheaper than 71.43% of the companies in the same industry.
  • PHI1 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 28.01, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 17.96
Fwd PE 17.47
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • PHI1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. PHI1 is cheaper than 66.67% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHI1 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 44.28
EV/EBITDA 13.73
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHI1 does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)3.63
PEG (5Y)N/A
EPS Next 2Y4.81%
EPS Next 3Y7.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PHI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KONINKLIJKE PHILIPS NV

FRA:PHI1 (2/11/2026, 7:00:00 PM)

26.58

-0.99 (-3.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04
Earnings (Next)02-10
Inst Owners44.83%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap25.59B
Revenue(TTM)17.78B
Net Income(TTM)165.00M
Analysts72.14
Price Target27.26 (2.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)-70.49%
DP199.39%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.57%
Min EPS beat(2)14.1%
Max EPS beat(2)31.04%
EPS beat(4)3
Avg EPS beat(4)13.85%
Min EPS beat(4)-11.97%
Max EPS beat(4)31.04%
EPS beat(8)3
Avg EPS beat(8)-0.89%
EPS beat(12)6
Avg EPS beat(12)18.79%
EPS beat(16)6
Avg EPS beat(16)4.51%
Revenue beat(2)0
Avg Revenue beat(2)-2.19%
Min Revenue beat(2)-2.4%
Max Revenue beat(2)-1.97%
Revenue beat(4)0
Avg Revenue beat(4)-2.34%
Min Revenue beat(4)-3.04%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-3.43%
Revenue beat(12)2
Avg Revenue beat(12)-1.64%
Revenue beat(16)2
Avg Revenue beat(16)-1.76%
PT rev (1m)-1.52%
PT rev (3m)-1.03%
EPS NQ rev (1m)1.37%
EPS NQ rev (3m)5.07%
EPS NY rev (1m)0.57%
EPS NY rev (3m)4.69%
Revenue NQ rev (1m)-0.52%
Revenue NQ rev (3m)-0.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.35%
Valuation
Industry RankSector Rank
PE 17.96
Fwd PE 17.47
P/S 1.44
P/FCF 44.28
P/OCF 20.86
P/B 2.43
P/tB N/A
EV/EBITDA 13.73
EPS(TTM)1.48
EY5.57%
EPS(NY)1.52
Fwd EY5.72%
FCF(TTM)0.6
FCFY2.26%
OCF(TTM)1.27
OCFY4.79%
SpS18.47
BVpS10.96
TBVpS-1.42
PEG (NY)3.63
PEG (5Y)N/A
Graham Number19.1
Profitability
Industry RankSector Rank
ROA 0.63%
ROE 1.56%
ROCE 5.61%
ROIC 3.95%
ROICexc 3.95%
ROICexgc 10.33%
OM 6.1%
PM (TTM) 0.93%
GM 43.49%
FCFM 3.25%
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y10.6%
ROICexgc growth 5Y-2.51%
ROICexc growth 3Y4.73%
ROICexc growth 5Y-6.98%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
F-ScoreN/A
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 14.51
Debt/EBITDA 2.93
Cap/Depr 46.69%
Cap/Sales 3.65%
Interest Coverage 250
Cash Conversion 49.6%
Profit Quality 350.3%
Current Ratio 1.32
Quick Ratio 0.86
Altman-Z 2.06
F-ScoreN/A
WACC6.49%
ROIC/WACC0.61
Cap/Depr(3y)50.01%
Cap/Depr(5y)53.78%
Cap/Sales(3y)3.94%
Cap/Sales(5y)4.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.15%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%12.5%
EPS Next Y4.94%
EPS Next 2Y4.81%
EPS Next 3Y7.44%
EPS Next 5Y10.28%
Revenue 1Y (TTM)-1.43%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-1.71%
Revenue Next Year-2.27%
Revenue Next 2Y0.25%
Revenue Next 3Y1.58%
Revenue Next 5Y3%
EBIT growth 1Y712.43%
EBIT growth 3Y0.03%
EBIT growth 5Y-7.17%
EBIT Next Year48.95%
EBIT Next 3Y19.49%
EBIT Next 5Y15.13%
FCF growth 1Y-45.51%
FCF growth 3Y-40.93%
FCF growth 5Y-1.73%
OCF growth 1Y-31.12%
OCF growth 3Y-32.38%
OCF growth 5Y-4.03%

KONINKLIJKE PHILIPS NV / PHI1.DE FAQ

What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.


What is the valuation status for PHI1 stock?

ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.


How profitable is KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 2 / 10.


How financially healthy is KONINKLIJKE PHILIPS NV?

The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 2 / 10.


Can you provide the dividend sustainability for PHI1 stock?

The dividend rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 0 / 10 and the dividend payout ratio is 199.39%.